Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in multiple myeloma.

S V Rajkumar1

  • 1Mayo Medical School, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA. rajks@mayo.edu

Oncology (Williston Park, N.Y.)
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2024
Same author

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.

Blood cancer journal·2023
Same author

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.

Blood cancer journal·2021
Same author

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.

Blood cancer journal·2021
Same author

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2021
Same author

N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression.

Leukemia·2020
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Thalidomide (Thalomid) shows activity in 25% to 35% of relapsed multiple myeloma patients, demonstrating its potential as an antiangiogenic therapy. Ongoing studies explore its use in initial treatment and combination therapies for this blood cancer.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma is characterized by increased angiogenesis, suggesting a therapeutic target.
  • Thalidomide (Thalomid) has emerged as a potential antiangiogenic agent for multiple myeloma treatment.

Purpose of the Study:

  • To summarize the current status of thalidomide therapy in multiple myeloma.
  • To review the efficacy, toxicities, and ongoing research of thalidomide in multiple myeloma.

Main Methods:

  • Review of clinical trials investigating thalidomide in relapsed and potentially newly diagnosed multiple myeloma.
  • Analysis of reported response rates and major toxicities associated with thalidomide treatment.

Main Results:

  • Thalidomide demonstrates activity in 25% to 35% of patients with relapsed multiple myeloma.

Related Experiment Videos

  • Responses are observed even in patients who have failed prior active regimens, including transplantation.
  • Common toxicities include constipation, sedation, rash, fatigue, and peripheral neuropathy.

    • Conclusions:

    • Thalidomide is an active agent in relapsed multiple myeloma, offering a valuable treatment option.
    • Further research is warranted to establish its role in initial therapy and in combination regimens.
    • Understanding thalidomide's mechanism of action in multiple myeloma remains an area of investigation.